93 related articles for article (PubMed ID: 288932)
1. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat.
McCullough HN; Juliano RL
J Natl Cancer Inst; 1979 Sep; 63(3):727-31. PubMed ID: 288932
[TBL] [Abstract][Full Text] [Related]
2. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.
Juliano RL; McCullough HN
J Pharmacol Exp Ther; 1980 Aug; 214(2):381-7. PubMed ID: 7391983
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.
Parker RJ; Priester ER; Sieber SM
Drug Metab Dispos; 1982; 10(1):40-6. PubMed ID: 6124381
[TBL] [Abstract][Full Text] [Related]
4. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
5. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
6. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
Rahman YE; Patel KR; Cerny EA; Maccoss M
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.
Juliano RL; Stamp D
Biochem Pharmacol; 1978 Jan; 27(1):21-7. PubMed ID: 619903
[No Abstract] [Full Text] [Related]
8. Treatment of intravenously implanted Lewis lung carcinoma with liposome-encapsulated cytosine arabinoside and non-specific immunotherapy.
Patel KR; Baldeschwieler JD
Int J Cancer; 1984 Sep; 34(3):415-20. PubMed ID: 6384069
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.
Kobayashi T; Kataoka T; Tsukagoshi S; Sakurai Y
Int J Cancer; 1977 Oct; 20(4):581-7. PubMed ID: 914397
[TBL] [Abstract][Full Text] [Related]
11. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size.
Hunt CA; Rustum YM; Mayhew E; Papahadjopoulos D
Drug Metab Dispos; 1979; 7(3):124-8. PubMed ID: 38080
[TBL] [Abstract][Full Text] [Related]
12. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
Kataoka T; Kobayashi T
Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of delivery of liposome-encapsulated cytosine arabinoside to CV-1 cells in vitro. Fluorescence-microscopic and cytotoxicity studies.
Brown PM; Silvius JR
Biochim Biophys Acta; 1990 Apr; 1023(3):341-51. PubMed ID: 2110480
[TBL] [Abstract][Full Text] [Related]
15. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
16. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation.
Jaafar-Maalej C; Diab R; Andrieu V; Elaissari A; Fessi H
J Liposome Res; 2010 Sep; 20(3):228-43. PubMed ID: 19899957
[TBL] [Abstract][Full Text] [Related]
17. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
18. Effect of vesicle size on the clearance, distribution, and tumor uptake of temperature-sensitive liposomes.
Magin RL; Hunter JM; Niesman MR; Bark GA
Cancer Drug Deliv; 1986; 3(4):223-37. PubMed ID: 3567843
[TBL] [Abstract][Full Text] [Related]
19. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
Ross DD; Chen SR; Cuddy DP
Cancer Res; 1990 May; 50(9):2658-66. PubMed ID: 2328491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
